Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Shares Outstanding (Diluted Average) (2021 - 2026)

Climb Bio filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $68.2 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.1% to $68.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $68.2 million through Mar 2026, up 1.1% year-over-year, with the annual reading at $67.8 million for FY2025, 40.8% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $68.2 million in Q1 2026 for Climb Bio, up from $67.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $68.2 million in Q1 2026 and bottomed at $26.2 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $41.1 million, with a median of $27.6 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding (Diluted Average) skyrocketed 656.55% in 2022 before it rose 0.97% in 2023.
  • Climb Bio's Shares Outstanding (Diluted Average) stood at $26.3 million in 2022, then grew by 2.57% to $27.0 million in 2023, then soared by 78.47% to $48.2 million in 2024, then soared by 40.8% to $67.8 million in 2025, then rose by 0.58% to $68.2 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Shares Outstanding (Diluted Average) are $68.2 million (Q1 2026), $67.8 million (Q4 2025), and $68.0 million (Q3 2025).